Social AdTech firm Mediads raises €3 million to accelerate its expansion into the US
Mediads, a pioneering social adtech company since 2022 specialising in social publishing, which
offers a platform designed to boost the performance of
Microbiotica reports positive results for MB097 in advanced melanoma
Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment.
Microbiotica has announced positive findings from its phase 1b MELODY‑1...
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-target in vivo immune therapies shown to induce a rapid, long-lasting and...
Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013
Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting...
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that the...
Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein
Paris, 31 March 2026 - Standing Ovation, a French precision fermentation pioneer producing next-
generation proteins, has announced a $34.2 million (€30 million) Series...
MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...
Citalid Secures U.S. Patent for Automated Cyberattack Simulation Powering Its CRQ Platform
Citalid, the leading cyber risk quantification (CRQ) tech provider in Europe, today announced the grant of U.S. Patent No. 12,542,803 B2 for a proprietary automated cyberattack...